ChemDiv has reached a development milestone in partnership with Viriom Inc. by advancing long acting injectable formulations of its lead HIV drug candidate, Elsulfavirine/VM1500A. Viriom will present the Latest Preclinical Data at the 16th European AIDS Conference in Milan, Italy, October 25-27, 2017.
The study evaluates new options for treatment and prevention of AIDS, especially for patients with resistant HIV strains, that would allow for infrequent dosing, thus facilitating patients’ adherence and likely improving long-term treatment outcomes. ChemDiv invites interested researchers and physicians to Viriom’s poster viewing session on Wednesday, October 25, 15:00 to 17:00. The study results will be presented by Dr. Kan and Dr. Bichko, CSO of Viriom.
The results of an earlier study, “Red Blood Cells are a Natural Slow Release Depot for Elsulfavirine/VM1500A HIV NNRTI”, were reported by Dr. Bichko at the 20th European Society for Clinical Virology (ESCV) annual meeting during the “HIV and Other Retroviruses” oral session on September 14 in Stresa, Italy. The study explained VM1500A beneficially long plasma elimination half-life after oral administration of Elsulfavirine.
“We are very excited about the latest clinical results and congratulate our partners at Viriom with the successful launch of Elpida® on October 5th within the framework of the 2nd St. Petersburg Forum on HIV/AIDS infection,” commented Rouslan Michtchenko, Sr. Director Business Development at ChemDiv. “We are proud that our robust unique and proprietary R&D platform helped Viriom deliver a drug candidate with virologic and immunologic efficacy in various formulations, combinations, and routs of administration, that can be used to safely and effectively treat patients even with drug-resistant HIV mutations or high viral load before treatment.”
“We are all pleased to see the results of our long term partnership with ChemDiv,” commented Nikolay Savchuk, Chairman of the Board of Viriom. “Elsulfavirine and VM1500A continue to demonstrate their potential as unique multidimensional therapeutic and prophylactic solutions for unmet needs in safe, effective and long acting regimens for HIV treatment. Viriom will continue to expand its pipeline of new life-saving treatments with the aim of developing an ultimate cure for HIV/AIDS worldwide.”
ChemDiv is a recognized global leader in discovery chemistry with one of the industry’s largest, most diverse, and most productive collections of over 1,600,000 lead-like small molecules. Over the past 25+ years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, immunology, cardio and metabolic diseases to its pharma and biotech customers around the globe. ChemDiv’s integrated drug discovery and evaluation platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond. http://www.chemdiv.com/
Viriom focuses on the treatment, prophylaxis, and eradication of infectious diseases globally. Viriom is developing and commercializing the most innovative and affordable solutions to radically expand global access to antiviral treatments and prophylaxis. Viriom’s broad, proprietary, and partnered pipeline covers therapeutic, prophylactic, and curative medicines for HIV/AIDS and other highly communicable diseases. Viriom’s most advanced drug is Elpida/Elsulfavirine, a once-daily 20 mg oral prodrug of VM-1500A, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI). Development is underway for once-weekly oral and longer-acting parenteral formulations of Elpida/Elsulfavirine, combination and formulations with VM-2500 proprietary pro-drug nucleoside inhibitor and other drugs. Learn more at www.viriom.com.